
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Novotech Health Holdings Pte. Ltd. (“Novotech”) has joined an alliance of over one hundred life sciences and healthcare organizations that seek to accelerate the broad adoption of patient-focused, decentralized trials, and research. The “Decentralized Trials & Research Alliance (DTRA),” launched in December 2020, is uniting industry stakeholders, including healthcare companies, regulators, patient groups and research organizations with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.






